Mycenax Biotech (4726.TWO) Earnings Analysis

Mycenax Biotech (4726.TWO) next reports earnings on 2026-08-06, consensus EPS -0.32 TWD. Last quarter (2026-03-10) it beat with EPS -0.26 TWD vs -0.33 TWD est (+21.2%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -11.71.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 4726.TWO next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.32 TWD
Revenue estimate0.21B

4726.TWO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-10-0.26 TWD-0.33 TWD+21.2%Beat
2025-11-10-0.63 TWD0.12 TWD-625%Miss
2025-03-12-0.40333 TWD-0.28 TWD-44%Miss
2024-08-09-0.49 TWD-0.63 TWD+22.2%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

4726.TWO valuation and analyst view

Trailing P/E-11.71
Trailing EPS-2.08936 TWD
Price / book3.47
Dividend yield0.00%
Market cap5.16B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Mycenax Biotech (4726.TWO)'s next earnings date?

Mycenax Biotech is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.32 TWD and revenue estimate of 0.21B.

Did 4726.TWO beat earnings last quarter?

In its 2026-03-10 report, 4726.TWO posted EPS of -0.26 TWD versus a -0.33 TWD estimate — a beat of 21.2%.

What is 4726.TWO's earnings track record?

Over the last 4 reported quarters with consensus data, 4726.TWO beat estimates 2 times (50%).

What is 4726.TWO's current P/E ratio and EPS?

4726.TWO trades at a trailing P/E of -11.71 on trailing EPS of -2.089361620648719 TWD.

What do analysts rate 4726.TWO?

4726.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.